Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Knowledge Synthesis Grant

McMaster University

$99,815.00

Use of Heparins in Cancer: Individual patient data meta-analysis

EF 2012-13

Résumé
Research evidence suggests that blood thinners may improve the survival of patients with cancer and reduce complications from blot clots that are more likely to develop in patients with cancer than without. This benefit could be related to a direct anti-tumor effect in addition to preventing blood clots that can travel to the lungs and lead to death. Our previous systematic review, based on summary data from studies, suggests that injectable blood thinners reduce the risk of blood clots by about half and possibly increase the risk of major bleeding by 30%, but the effect on survival remains unclear and we do not know which subgroups may benefit in particular. The main limitations of prior systematic review are the relatively small number of included trials and the inclusion of different types and stages of cancer that can not be separated in systematic summaries of data from studies only. For this review we will strive obtain data on individual patients from all studies that have been conducted on this topic and analyze the data based on each single patient. At least 11 studies, some of them large, exist on this topic.
Programme
Knowledge Synthesis Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
269788
Name
Schunemann Holger J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Knowledge Synthesis Grant
Projecttitle
Use of Heparins in Cancer: Individual patient data meta-analysis
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$99,815
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant
Keyworddelim
Anticoagulants; Cancer; Individual Patient Data; Systematic Review
Abstract
Research evidence suggests that blood thinners may improve the survival of patients with cancer and reduce complications from blot clots that are more likely to develop in patients with cancer than without. This benefit could be related to a direct anti-tumor effect in addition to preventing blood clots that can travel to the lungs and lead to death. Our previous systematic review, based on summary data from studies, suggests that injectable blood thinners reduce the risk of blood clots by about half and possibly increase the risk of major bleeding by 30%, but the effect on survival remains unclear and we do not know which subgroups may benefit in particular. The main limitations of prior systematic review are the relatively small number of included trials and the inclusion of different types and stages of cancer that can not be separated in systematic summaries of data from studies only. For this review we will strive obtain data on individual patients from all studies that have been conducted on this topic and analyze the data based on each single patient. At least 11 studies, some of them large, exist on this topic.
Competitiondate
201210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schunemann, Holger J; Akl, Elie A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,815~ $0~